Tech Company Financing Transactions
Kyn Therapeutics Funding Round
On 12/15/2017, Kyn Therapeutics received $49 million in Series A funding from Atlas Venture and OrbiMed.
Transaction Overview
Company Name
Announced On
12/15/2017
Transaction Type
Venture Equity
Amount
$49,000,000
Round
Series A
Investors
Proceeds Purpose
The firm's first clinical study will initiate in 2018.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1030 Massachusetts Ave. 400
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
Kyn Therapeutics is developing cancer therapies focused on metabolic pathways that influence the innate and adaptive immune systems.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Manfredi
Chief Medical Officer
Jason Sager
Vice President
Alfredo Castro
Vice President
Karen McGovern
VP - Operations
James Nolan
VP - R & D
Jeffrey Ecsedy
VP - R & D
Michelle Zhang
Browse more venture capital transactions:
Prev: 12/15/2017: Glo Station venture capital transaction
Next: 12/15/2017: Curisium venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs